Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical News Today (MNT)
Claims that semaglutide microdosing works to maintain weight loss and manage blood sugar are mainly anecdotal and not backed by scientific research.
Clinical Pharmacology April 9th 2025
Cleveland Clinic Journal of Medicine (CCJM)
In the absence of contraindications, metformin should be seriously considered as an off-label initial therapy and as an adjunct to antiobesity medications approved by the US Food and Drug Administration.
Endocrinology, Diabetes, Metabolism April 2nd 2025
MDLinx
“It isn’t easy to kick this… Because porn shrinks your world.” —Aline Zoldbrod, PhD
Family Medicine/General Practice April 1st 2025
Adverse events from compounded semaglutide have led to hundreds of hospitalizations, highlighting critical safety concerns for healthcare providers managing patients seeking weight loss solutions.
Endocrinology, Diabetes, Metabolism November 20th 2024
GLP-1 receptor agonists, beyond their role in diabetes and obesity management, are showing promise in reducing alcohol cravings, potentially offering a novel approach to treating alcohol use disorder.
Endocrinology, Diabetes, Metabolism June 4th 2024
Psychiatry Advisor
Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.
Psychiatry May 21st 2024